Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR ) Q2 2025 Earnings Conference Call May 12, 2025 4:30 PM ET Company Participants Vincent Anzalone - Vice President of Investor Relations for Arrowhead Christopher Anzalone - President & CEO Bruce Given - Interim Chief Medical Scientist Andy Davis - SVP & Head of Global Cardio/Metabolic Franchise James Hamilton - Chief Discovery & Translational Medicine Ken Myszkowski - Outgoing CFO Daniel Apel - Incoming CFO Conference Call Participants Maury Raycroft - Jefferies Jason Gerberry - Bank of America Jasmine Fels - UBS Patrick Trucchio - H.C. Wainwright & Company Luca Issi - RBC Edward Tenthoff - Piper Sandler Mike Ulz - Morgan Stanley Mayank Mamtani - B.
Arrowhead Pharmaceuticals, Inc. has streamlined its focus, now boasting 19 clinical programs, including 4 phase 3 trials and 4 phase 2 trials. Plozasiran shows superior results in triglyceride reduction and dosing frequency compared to its main competitor, Olezarsen, with a pivotal PDUFA date on November 18. ARWR's strong financial position is bolstered by a recent deal with Sarepta, extending its cash runway into 2028.
Arrowhead Pharmaceuticals is executing on the clinical and regulatory side during adverse market conditions for biotech companies and genetic stocks in particular. Zodasiran is back in the clinic with a phase 3 trial plan in homozygous familiar hypercholesterolemia patients. We could see as many as three phase 1/2 readouts this year from programs that were recently partnered with Sarepta, and ARO-DM1 program milestones point to registrational intent.
14 Aug 2025 (In 1 month) Date | | - Cons. EPS | - EPS |
11 Aug 2025 (In 4 weeks) Date | | - Cons. EPS | - EPS |
7 May 2025 Date | | - Cons. EPS | 2.75 EPS |
4 Feb 2025 Date | | - Cons. EPS | - EPS |
27 Nov 2024 Date | | - Cons. EPS | - EPS |
14 Aug 2025 (In 1 month) Date | | - Cons. EPS | - EPS |
11 Aug 2025 (In 4 weeks) Date | | - Cons. EPS | - EPS |
7 May 2025 Date | | - Cons. EPS | 2.75 EPS |
4 Feb 2025 Date | | - Cons. EPS | - EPS |
27 Nov 2024 Date | | - Cons. EPS | - EPS |
Biotechnology Industry | Healthcare Sector | Christopher R. Anzalone CEO | XDUS Exchange | US04280A1007 ISIN |
US Country | 609 Employees | - Last Dividend | 17 Nov 2011 Last Split | 16 Jun 1993 IPO Date |
Arrowhead Pharmaceuticals, Inc. is a pioneering company focused on the development of innovative medicines for the treatment of intractable diseases. With a comprehensive pipeline of products undergoing various stages of clinical trials, the company is at the forefront of addressing challenging health conditions that impact populations in the United States. Arrowhead is dedicated to finding novel therapeutic solutions for patients with a range of diseases, leveraging cutting-edge research and strategic collaborations. Established in 2003 and based in Pasadena, California, the organization has formed key partnerships with industry leaders to advance its mission of bringing groundbreaking treatments to market.
Arrowhead Pharmaceuticals, Inc.'s robust pipeline encompasses a variety of products, each targeting specific intractable diseases through different stages of clinical development:
Moreover, Arrowhead Pharmaceuticals has entered into strategic license and research collaboration agreements with notable entities including Janssen Pharmaceuticals, Inc., Takeda Pharmaceutical Company Limited, Horizon Therapeutics Ireland DAC, Amgen Inc., and GlaxoSmithKline Intellectual Property (No. 3) Limited, underscoring its collaborative and innovative approach to drug development.